Close Menu
  • FDA
  • Conferences
    • AACR
    • ASBRS
    • ASCO
    • SABCS
    • ASH
    • ESMO
    • MOASC
    • Upcoming Oncology Conferences
  • Cancers
    • Breast Cancer
    • Prostate Cancer Treatment
    • Lung Cancer Treatment
    • Gastrointestinal Cancer Treatment
    • Melanoma Skin Cancer Treatment
    • Non-Hodgkin Lymphoma
    • Kidney
    • Acute Lymphoblastic Leukemia
    • Acute Myelogenous Leukemia
    • Bone Metastases
    • Brain
    • Business Management
    • Cervical
    • Chronic Lymphocytic Leukemia
    • Chronic Myelogenous Leukemia
    • Colorectal
    • COVID-19
    • General
    • Genitourinary
    • Head and Neck
    • Help
    • Hematologic Malignancies
    • Hodgkin Lymphoma
    • Imaging
    • Immunotherapy
    • Liver
    • Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Disease
    • News
    • Non-Small Cell Lung Cancer
    • Other
    • Ovarian
    • Pancreatic
    • Patient Resources
    • Pediatric
    • Sarcoma
    • Sickle Cell
    • Small Cell Lung Cancer
    • Supportive Care
    • Testicular
    • Urology
    • Uterine
  • About
  • Contact
  • Advertise
    • Advertising & Services – Media Kit 2025 OncologyTube.com
    • Oncology Press Release Distribution
Advertisement
X (Twitter) LinkedIn Facebook
X (Twitter) LinkedIn Facebook YouTube
OncologyTube
  • FDA
  • Conferences
    • AACR
    • ASBRS
    • ASCO
    • SABCS
    • ASH
    • ESMO
    • MOASC
    • Upcoming Oncology Conferences
  • Cancers
    • Breast Cancer
    • Prostate Cancer Treatment
    • Lung Cancer Treatment
    • Gastrointestinal Cancer Treatment
    • Melanoma Skin Cancer Treatment
    • Non-Hodgkin Lymphoma
    • Kidney
    • Acute Lymphoblastic Leukemia
    • Acute Myelogenous Leukemia
    • Bone Metastases
    • Brain
    • Business Management
    • Cervical
    • Chronic Lymphocytic Leukemia
    • Chronic Myelogenous Leukemia
    • Colorectal
    • COVID-19
    • General
    • Genitourinary
    • Head and Neck
    • Help
    • Hematologic Malignancies
    • Hodgkin Lymphoma
    • Imaging
    • Immunotherapy
    • Liver
    • Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Disease
    • News
    • Non-Small Cell Lung Cancer
    • Other
    • Ovarian
    • Pancreatic
    • Patient Resources
    • Pediatric
    • Sarcoma
    • Sickle Cell
    • Small Cell Lung Cancer
    • Supportive Care
    • Testicular
    • Urology
    • Uterine
  • About
  • Contact
  • Advertise
    • Advertising & Services – Media Kit 2025 OncologyTube.com
    • Oncology Press Release Distribution
Subscribe
OncologyTube
Home » John P. Pierce, PhD @UCSDCRCERA #Smoking #Cancer #Research Does switching to e-Cigarettes Prevent Relapse?
Other

John P. Pierce, PhD @UCSDCRCERA #Smoking #Cancer #Research Does switching to e-Cigarettes Prevent Relapse?

EditorBy EditorOctober 21, 2021No Comments4 Mins Read
Twitter LinkedIn Facebook Email
Share
Twitter LinkedIn Facebook Email

Ask about FDA oncology approvals, clinical trials, and treatment guidelines.

John P. Pierce, Ph.D., Professor Emeritus, Moores UCSD Cancer Center speaks about Does switching to e-Cigarettes Prevent Relapse?

Link to Abstract:
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2785237?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=101921

Points to Remember –

Is switching to e-cigarettes linked to a lower risk of relapsing into cigarette smoking?

Findings:
In this cohort research of a representative sample of US people, 9.4% of those who smoked cigarettes 1 year later were recent former smokers. Switching to any tobacco product, including e-cigarettes, was linked to an 8.5 percent increase in relapse to smoking over the next year, which was similar to the rise reported in people who moved to conventional tobacco products.

Meaning:
In adults in the United States, switching to e-cigarettes is not linked to reduced cigarette smoking relapse.

Summary –

Despite the fact that e-cigarettes have not been certified as a cessation aid, many smokers believe that they will assist them in effectively quitting cigarettes.

The goal of this study was to see if those who had recently stopped smoking and transitioned to e-cigarettes or another tobacco product were less likely to relapse than those who had stayed tobacco-free.

Design, Setting, and Participants:
This cohort study looked at a nationally representative sample of US households that took part in four waves of the Population Assessment of Tobacco and Health Study (from 2013 to 2017), each with three yearly surveys. Individuals who smoked at baseline had recently quit at the first follow-up and completed the second follow-up survey were all eligible.

Exposures:
Use of e-cigarettes or other tobacco products after stopping smoking for the first time at follow-up 1.

Main Outcomes and Measures:
Weighted percentage of participants who have been abstinent for more than 12 months at the follow-up 2.

Results:
Of the 13 604 participants who smoked cigarettes at the start of the study, 9.4% (95 percent confidence interval: 8.7%-10.0 percent) had recently quit smoking (mean age, 41.9; 95 percent CI, 39.7-46.6 years; 641 [43.2 percent ] women) 22.8 percent (95 percent confidence interval: 19.7 percent -26.0 percent) had shifted to e-cigarettes, with 17.6 percent (95 percent confidence interval: 14.8 percent -20.5 percent) using them on a daily basis. A total of 37.1 percent (95 percent CI, 33.7 percent -40.4 percent ) used a non-cigarette tobacco product, whereas 62.9 percent (95 percent CI, 59.6 percent -66.3 percent ) did not. Switching to e-cigarettes was most common among those in the top tertile of tobacco dependence (31.3 percent; 95 percent CI, 25.0 percent -37.7%), non-Hispanic White (26.4 percent; 95 percent CI, 22.3 percent -30.4 percent), and those with higher incomes ($35 000, 27.5 percent; 95 percent CI, 22.5 percent -32.4 percent vs. $35 000, 19.3 percent; 95 percent CI, 16.3 percent At the second follow-up, the unadjusted relapse rates among those who switched to different cigarette products were similar (for any tobacco product: successfully quit, 41.5 percent; 95 percent CI, 36.2 percent -46.9 percent; relapsed with significant requit, 17.0 percent; 95 percent CI, 12.4 percent -21.6 percent; currently smoking, 36.2 percent; 95 percent CI, 30.9 percent -41.4 percent ). When relevant confounders were taken into account, switching to any tobacco product was linked to a higher rate of relapse than staying tobacco-free (adjusted risk difference, 8.5 percent; 95 percent CI, 0.3 percent -16.6 percent ). The number of people who switched to e-cigarettes, whether they did so on a daily basis or not, was not substantial. While smokers who transitioned to e-cigarettes were more likely to relapse, they also looked to be more likely to stop and be abstinent for three months at follow-up 2. (17.0 percent; 95 percent CI, 12.4 percent -21.6 percent vs 10.4 percent; 95 percent CI, 8.0 percent -12.9 percent ).

Conclusions and Implications:
The premise that switching to e-cigarettes will prevent relapse to cigarette smoking is not supported by this large, nationally representative study from the United States.

Follow on X (Twitter) Follow on LinkedIn Follow on Facebook Follow on Google News
Share. Twitter LinkedIn Facebook Email

Related Posts

Image showing pathology of ICI myocarditis with visible heart inflammation, researched by UCSF experts.

Immune Checkpoint Inhibitors Myocarditis: 1% Risk, 50% Fatal – UCSF Insights

Other 3 Mins Read
A gorgeous female doctor in a white coat holding up a pill and looking straight at the camera, with a purple background. An FDA APPROVED badge and text overlay reads: 'FDA approves Vimseltinib / Romvimza from Deciphera for symptomatic TGCT' in blue and orange text

FDA Approves Deciphera Vimseltinib / Romvimza for symptomatic tenosynovial giant cell tumor (TGCT) patients

Other 2 Mins Read
Image showing the FDA approval logo with text "FDA Approves Mirdametinib/Gomekli for NF1-PN: Data Overview" alongside a healthcare professional in blue scrubs holding a pill.

FDA Approves Mirdametinib: Is this the Breakthrough NF1-PN Patients Have Been Waiting For?

Other 3 Mins Read
Connect With Us on Social
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube

Latest FDA Oncology Updates

Accepted for Review Oncology Press Release

FDA Accepts NDA for TLX101-Px (Pixclara®) - PR Newswire

FDA Accepts NDA for TLX101-Px (Pixclara®). (PRNewsfoto/Telix Pharmaceuticals ... cancer), and has assigned a PDUFA goal date of September 11, 2026 ...

Filed: Sep 11, 2026 View source on FDA.gov →
ODAC Meeting Oncology FDA ODAC

April 30, 2026: Meeting of the Oncologic Drugs Advisory Committee

Event Title. April 30, 2026: Meeting of the Oncologic Drugs Advisory Committee Meeting Announcement. April 30, 2026 · On This Page · Agenda · Meeting Materials.

Meeting: Apr 30, 2026 View source on FDA.gov →
PDUFA Date Oncology Press Release

Savara Announces the U.S. Food & Drug Administration (FDA) Has ...

Such statements include, but are not limited to, statements related to the target PDUFA action date. Savara may not actually achieve any of the matters ...

View source on FDA.gov →
Approval Heme FDA OCE

FDA approves nivolumab with chemotherapy for Hodgkin lymphoma

This review was conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence. Project Orbis provides a framework for concurrent ...

View source on FDA.gov →
News Oncology FDA OCE

FDA Oncology Center of Excellence Presents Conversations on ...

FDA Oncology Center of Excellence Presents Conversations on Cancer: Oncology Nurses - Frontliners in Oncology May 6, 2026.

View source on FDA.gov →
News Oncology FDA OCE

FDA Schedules Public Meeting on the Commissioner's National ...

... Oncology Center of Excellence, as well as a presiding officer. Requests to speak are due by April 24 at 11:59 p.m. The FDA is also soliciting written ...

View source on FDA.gov →
Approval GYN FDA.gov

FDA approves relacorilant with nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer

On March 25, 2026, the Food and Drug Administration approved relacorilant (Lifyorli, Corcept Therapeutics Inc.), a glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.

Approved: Mar 25, 2026 View source on FDA.gov →
Approval Heme FDA.gov

FDA approves nivolumab with chemotherapy for previously untreated Hodgkin lymphoma

On March 20, 2026, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with doxorubicin, vinblastine, and dacarbazine (AVD) for adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgkin lymphoma (cHL).

Approved: Mar 20, 2026 View source on FDA.gov →
Recent Posts
  • Does QHS-5132 Signal a Biomarker-Agnostic Shift in Ovarian Cancer Treatment?
  • Is Alisertib the New Standard for Overcoming Resistance in KRAS G12C-Mutant NSCLC?
  • Can Zoldonrasib Redefine Treatment for KRAS G12D NSCLC?
  • Are We Under-Treating PE in Cancer Patients?
  • Is MammaPrint High Risk the New Standard for Guiding Immunotherapy?
X (Twitter) LinkedIn Facebook YouTube
  • FDA
  • Conferences
    • AACR
    • ASBRS
    • ASCO
    • SABCS
    • ASH
    • ESMO
    • MOASC
    • Upcoming Oncology Conferences
  • Cancers
    • Breast Cancer
    • Prostate Cancer Treatment
    • Lung Cancer Treatment
    • Gastrointestinal Cancer Treatment
    • Melanoma Skin Cancer Treatment
    • Non-Hodgkin Lymphoma
    • Kidney
    • Acute Lymphoblastic Leukemia
    • Acute Myelogenous Leukemia
    • Bone Metastases
    • Brain
    • Business Management
    • Cervical
    • Chronic Lymphocytic Leukemia
    • Chronic Myelogenous Leukemia
    • Colorectal
    • COVID-19
    • General
    • Genitourinary
    • Head and Neck
    • Help
    • Hematologic Malignancies
    • Hodgkin Lymphoma
    • Imaging
    • Immunotherapy
    • Liver
    • Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Disease
    • News
    • Non-Small Cell Lung Cancer
    • Other
    • Ovarian
    • Pancreatic
    • Patient Resources
    • Pediatric
    • Sarcoma
    • Sickle Cell
    • Small Cell Lung Cancer
    • Supportive Care
    • Testicular
    • Urology
    • Uterine
  • About
  • Contact
  • Advertise
    • Advertising & Services – Media Kit 2025 OncologyTube.com
    • Oncology Press Release Distribution
© 2026 Copyright Protected Medicus Networks, Inc. Privacy Policy

Type above and press Enter to search. Press Esc to cancel.